Morphic Holding, Inc. (MORF)
Market Cap | 1.55B |
Revenue (ttm) | 70.81M |
Net Income (ttm) | -59.04M |
Shares Out | 41.52M |
EPS (ttm) | -1.55 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 570,221 |
Open | 37.33 |
Previous Close | 37.63 |
Day's Range | 35.89 - 37.64 |
52-Week Range | 19.23 - 49.24 |
Beta | 1.18 |
Analysts | Buy |
Price Target | 60.18 (+61.69%) |
Earnings Date | May 2, 2023 |
About MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibroti... [Read more]
Financial Performance
In 2022, MORF's revenue was $70.81 million, an increase of 257.72% compared to the previous year's $19.79 million. Losses were -$59.04 million, -38.20% less than in 2021.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is $60.18, which is an increase of 61.69% from the latest price.
News

Morphic to Present at TD Cowen 43rd Annual Health Care Conference
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chron...

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23-

Morphic to Present at SVB Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chroni...

Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...

Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chroni...

Morphic Announces Participation in 2022 Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...

Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 2.50% and 46.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc...

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule

Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
Saturating receptor occupancy at 100 and 200 mg BID doses

Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible Phase 2a trial of MORF-057 in patients with ulcera...

Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations

Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...

Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree
Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders

Morphic Celebrates Foundational Integrin Research Published in Cell
Paper describes key insight into integrin conformation, overcoming critical drug development challenge

Wall Street Analysts Predict a 108% Upside in Morphic Holding, Inc. (MORF): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questiona...

Can Morphic Holding, Inc. (MORF) Climb 97% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 96.7% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionab...

Morphic Holding, Inc. (MORF) Surpasses Q2 Earnings and Revenue Estimates
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc...

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022
Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis

Morphic Holding, Inc. (MORF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Morphic Holding, Inc. (MORF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Morphic to Present at 2022 Jefferies Global Healthcare Conference
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...

Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs
Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Therapeutic Areas Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple ...

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -19.72% and 52.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022
Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis

Strength Seen in Morphic Holding, Inc. (MORF): Can Its 7% Jump Turn into More Strength?
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...

Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious c...